Shots:

• The NMPA has approved Byvasda for the treatment of adult recurrent Glioblastoma which is the third approved indication of Byvasda in China
• The launch of Byvasda has provided Chinese patients with high quality and relatively more affordable bevacizumab biosimilar injection
• Byvasda is a bevacizumab biosimilar and a recombinant humanized anti-VEGF monoclonal antibody drug. Byvasda has been approved in China for the treatment of NSCLC and mCRC

 ­ Ref: Innovent  | Image: Innovent